Literature DB >> 15064704

Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells.

Oleg I Tchernitsa1, Christine Sers, Johannes Zuber, Bernd Hinzmann, Martin Grips, Anja Schramme, Per Lund, Anke Schwendel, André Rosenthal, Reinhold Schäfer.   

Abstract

To understand the relationship between oncogenic signaling and the reprogramming of gene expression, we performed transcriptional profiling in rat ovarian surface epithelial cells (ROSE), in which neoplastic transformation is driven by a mutated KRAS oncogene. We identified >200 genes whose expression was elevated or reduced following permanent KRAS expression. Deregulated KRAS-responsive genes encode transcriptional regulators, signaling effectors, proteases, extracellular matrix and adhesion proteins, transformation-suppressing proteins and negative growth regulators. Many of them have not been previously identified in cells expressing oncogenic RAS genes or in other well-studied models of oncogenic signaling. The number of critical genes related to the execution of anchorage-independent proliferation and epithelial-mesenchymal transition was narrowed down to 79 by selectively inhibiting the mitogen-activated protein kinase (MAPK/ERK) and phosphatidylinositol 3-kinase (PI3K) pathways. Blocking MAPK/ERK-signaling caused reversion to the normal epithelial phenotype in conjunction with the reversal of deregulated target transcription to pretransformation levels. In addition, silencing of the overexpressed transcriptional regulator Fra-1 by RNA interference resulted in growth reduction, suggesting that this factor partially contributes to, but is not sufficient for the proliferative capacity of KRAS-transformed epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064704     DOI: 10.1038/sj.onc.1207585

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

Review 1.  Expression and function of FRA1 protein in tumors.

Authors:  Xiaoyan Jiang; Hui Xie; Yingyu Dou; Jing Yuan; Da Zeng; Songshu Xiao
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

2.  Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells.

Authors:  Putty-Reddy Sudhir; Chein-Hung Chen; Madireddy Pavana Kumari; Mei-Jung Wang; Chih-Chiang Tsou; Ting-Yi Sung; Jeou-Yuan Chen; Chung-Hsuan Chen
Journal:  Mol Cell Proteomics       Date:  2012-07-03       Impact factor: 5.911

3.  Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells.

Authors:  Karsten Jürchott; Ralf-Jürgen Kuban; Till Krech; Nils Blüthgen; Ulrike Stein; Wolfgang Walther; Christian Friese; Szymon M Kiełbasa; Ute Ungethüm; Per Lund; Thomas Knösel; Wolfgang Kemmner; Markus Morkel; Johannes Fritzmann; Peter M Schlag; Walter Birchmeier; Tammo Krueger; Silke Sperling; Christine Sers; Hans-Dieter Royer; Hanspeter Herzel; Reinhold Schäfer
Journal:  PLoS Genet       Date:  2010-12-02       Impact factor: 5.917

Review 4.  Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression.

Authors:  Marcus E Peter
Journal:  Cell Cycle       Date:  2009-03-22       Impact factor: 4.534

5.  Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis.

Authors:  Roderick P Regala; Rebecca K Davis; Alyssa Kunz; Andras Khoor; Michael Leitges; Alan P Fields
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

6.  Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

Authors:  Michael S Anglesio; Jeremy M Arnold; Joshy George; Anna V Tinker; Richard Tothill; Nic Waddell; Lisa Simms; Bianca Locandro; Sian Fereday; Nadia Traficante; Peter Russell; Raghwa Sharma; Michael J Birrer; Anna deFazio; Georgia Chenevix-Trench; David D L Bowtell
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

7.  HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties.

Authors:  Christian V Recktenwald; Sandra Leisz; André Steven; Kousaku Mimura; Anja Müller; Jens Wulfänger; Rolf Kiessling; Barbara Seliger
Journal:  J Biol Chem       Date:  2012-05-11       Impact factor: 5.157

8.  Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines.

Authors:  Steffan Vartanian; Carolyn Bentley; Matthew J Brauer; Li Li; Senji Shirasawa; Takehiko Sasazuki; Jung-Sik Kim; Pete Haverty; Eric Stawiski; Zora Modrusan; Todd Waldman; David Stokoe
Journal:  J Biol Chem       Date:  2012-11-27       Impact factor: 5.157

Review 9.  Ras proteins: paradigms for compartmentalised and isoform-specific signalling.

Authors:  J Omerovic; A J Laude; I A Prior
Journal:  Cell Mol Life Sci       Date:  2007-10       Impact factor: 9.261

10.  Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS.

Authors:  Iwona Stelniec-Klotz; Stefan Legewie; Oleg Tchernitsa; Franziska Witzel; Bertram Klinger; Christine Sers; Hanspeter Herzel; Nils Blüthgen; Reinhold Schäfer
Journal:  Mol Syst Biol       Date:  2012       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.